The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).
 
Timothy F. Burns
Consulting or Advisory Role - Advarra; Amgen; AstraZeneca; Blueprint Medicines; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Mirati Therapeutics; Takeda
Speakers' Bureau - Amgen
 
Hong Wang
No Relationships to Disclose
 
Drew Hurd
No Relationships to Disclose
 
Madison Nguyen
No Relationships to Disclose
 
Liza C Villaruz
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; EMD Serono; Gilead Sciences; Janssen Oncology; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Sanofi/Regeneron; Takeda
Research Funding - AstraZeneca (Inst); BioAtla (Inst); BMS (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Regeneron (Inst)
 
Daniel P. Petro
Stock and Other Ownership Interests - cytoagents; Duo Oncology; Elucida Oncology; ImmunityBio
Consulting or Advisory Role - IntegraConnect
 
Marc B. Schwartz
No Relationships to Disclose
 
Howard M. Dubner
No Relationships to Disclose
 
Hassane M. Zarour
Honoraria - maat pharma
Consulting or Advisory Role - Checkmate Pharmaceuticals
Research Funding - Merck Sharp & Dohme (Inst); Tesaro (Inst)
 
Giorgio Trinchieri
No Relationships to Disclose
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy